Who is sponsoring NCT03627052?

NCT03627052 is sponsored by Incyte Corporation.

What drugs are being tested in NCT03627052?

Interventions in NCT03627052: Itacitinib, Placebo.

What condition does NCT03627052 study?

NCT03627052 studies Moderate to Severe Ulcerative Colitis.

Is NCT03627052 still recruiting?

NCT03627052 is currently withdrawn. Last updated 6 December 2019.

Last reviewed 2019-12-06 · How we verify

NCT03627052

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

Withdrawn Phase 2 Last updated 6 December 2019

What this trial tests

Phase 2 trial testing Itacitinib in Moderate to Severe Ulcerative Colitis. Withdrawn.

Timeline

20 September 2018

Primary endpoint
13 November 2019

13 November 2019

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	20 September 2018
Primary completion	13 November 2019
Estimated completion	13 November 2019

Drugs / interventions tested

Itacitinib — full drug profile →
Placebo

Conditions studied

Moderate to Severe Ulcerative Colitis — all drugs for Moderate to Severe Ulcerative Colitis →

Sponsor

Incyte Corporation — full company profile →

Who can join

Adults 18 to 74, any sex, with Moderate to Severe Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of itacitinib in participants with moderate to severe ulcerative colitis (UC).

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment.
Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, et al · · 2021 · cited 33× · PMID 34884361 · DOI 10.3390/jcm10235660
Efficacy of JAK inhibitors in Ulcerative Colitis.
Ferrante M, Sabino J. · · 2020 · cited 25× · PMID 31879750 · DOI 10.1093/ecco-jcc/jjz202
Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors.
Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, et al · · 2020 · cited 21× · PMID 32440190 · DOI 10.2147/ceg.s208020
Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease.
Tian Z, Zhao Q, Teng X. · · 2024 · cited 13× · PMID 39086483 · DOI 10.3389/fimmu.2024.1393463
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC, Hussein IM, Nguyen TM, Parker CE, et al · · 2020 · cited 9× · PMID 31984480 · DOI 10.1002/14651858.cd012381.pub2
Advancing therapeutic frontiers: a pipeline of novel drugs for UC management.
Bertin L, Massano A, Redavid C, Scarpa M, et al · · 2026 · PMID 41822012 · DOI 10.3389/fgstr.2026.1747118

Verify or expand the search:

Other trials of Itacitinib

Trials testing the same drug.

NCT05660421 — Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors · Phase 2 · withdrawn
NCT05364762 — Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergo · Phase 2 · active not recruiting
NCT05063110 — Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB · Phase 2 · completed
NCT04859946 — Itacitinib for the Prevention of Graft Versus Host Disease · Phase 2 · active not recruiting
NCT04239989 — Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant · Phase 1 · terminated

Other recruiting trials for Moderate to Severe Ulcerative Colitis

Currently open trials in the same condition.

NCT06693908 — A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Co · Phase 1, PHASE2 · recruiting
NCT05486104 — Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis · Phase 2 · active not recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03627052 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 6 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03627052.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing